#ACR25 Please find my video interview with Prof Edward Vital @edvital on their work on International Consensus of Glucocorticoid Tapering Guideline in #SLE #lupus Abstr#1526 @RheumNow https://t.co/MnQdcdASkG https://t.co/b7GMcnFU2m

• Putting Steroid Tapering into Practice in SLE
• https://x.com/Yuz6Yusof/status/1983151495173550130/photo/1

#ACR25 Please find my video and take on Abstr#0646. Promising new Bi-specific T-cell engager (BiTE) other than Blinatumomab in #SLE @RheumNow https://t.co/5JrLG41nsD https://t.co/KeY6AkHUNK

• Progressive BiTE in SLE 2
• https://x.com/Yuz6Yusof/status/1983150449952768008/photo/1

#ACR25 Please find my video and take on Abstr#0803. Should we use Belimumab before- or after a trial of concentional immunosuppressant in #SLE? @RheumNow https://t.co/ExIvrdJXw5 https://t.co/AVb5ohWwXZ

• Belimumab Before or After Immunosuppressant | RheumNow
• https://x.com/Yuz6Yusof/status/1983149200066904516/photo/1

Progressive BiTE in SLE 2 https://t.co/ykMQmSAdlb More on BiTES in SLE by the one and only @Yuz6Yusof Bi specific Tcell engager ( CD3-CD19). @RheumNow #ACR25

• Progressive BiTE in SLE 2

Abstract 1718: Immune checkpoint inhibitors (ICI) in pre-existing #SLE Compared to non-SLE pts, those with SLE receiving ICIs had: 🔹 ↑ risk of thrombocytopenia & pancytopenia 🔹 No significant difference in all-cause mortality @RheumNow #ACR25 https://t.co/N1iOvxbsAZ

• https://x.com/AkhilSoodMD/status/1982921999350718964/photo/1

#ACR25 Abstr#1532 “The more the merrier” or “Too many cooks..” Preliminary data of CTA313, dual CD19-BCMA CAR-T in 15 #SLE pts showed deep depletion & good response. Global study is planned. Will have to keep on eye on safety (G3 herpes zoster, pneumonia & neutropenia) @RheumNow https://t.co/0KQa9K6bYB

• https://x.com/Yuz6Yusof/status/1982900831436615909/photo/1

#ACR25 SMILE RCT of Incomplete #SLE (ANA+ but not meeting SLICC) showed HCQ didn’t slow down SLE progression. But multiplex arrays showed reduction in autoantibodies with HCQ that were distinct from abs assoc. w progression. Would biomarker endpoints be the answer? @RheumNow https://t.co/XcvacgObVo

• https://x.com/Yuz6Yusof/status/1982864787144093994/photo/1

Global survey from the 2024 Adelphi Lupus Dse Specific Programme evaluated pt burden & MD/Pt Tx preferences: Efficacy & safety - top 2 MD-reported reasons for tx initiation OD, oral dosing-most preferred mode by MD & Pts Shared decision-making is key #ACR25 @RheumNow Abs1551 https://t.co/rmpCATCa78

• https://x.com/RHEUMarampa/status/1982856065696862239/photo/1

This poster is absolutely bonkers & I LOVE it Huge table. Frequency of everything over time Really interesting to see which activity persists / how much damage is accumulated Every trial should be obligated to share this (esp SLE!) #ACR25 @RheumNow #ACRBest Abst#1608 https://t.co/blRrvwi3qP

• https://x.com/EBRheum/status/1982854554925293910/photo/1

Interim analysis of Ph3 TULIP-SC trial: Anifrolumab 120mg SC or PBO weekly + SOC x 52wks Primary endpt met: BICLA response w/Anifrolumab (60.3%) vs. PBO(43.9%)[p=0.014] Pts on Ani had sustained BICLA response upto wk 52 (HR 2.1) Promising results. #ACR25 @RheumNow Abs1545 https://t.co/nqse1BiGq2

• https://x.com/RHEUMarampa/status/1982853044934225957/photo/1
• https://x.com/RHEUMarampa/status/1982853044934225957/photo/1